Open in interactive viewer → charts, metric popovers & call review

Quanterix Finds Its Bottom — Just Not the FDA's

First sequential growth in four quarters, a Florida Medicaid reimbursement win, and a 510(k) clock that quietly stopped ticking
QTRX · Earnings Call · 2026-11-09

Quanterix Finds Its Bottom — Just Not the FDA's

Quanterix is a $137 million market-cap shell of what it once was: a stock down 96% from its February 2021 peak of $90.64, and another 21% over the last ninety trading days alone. So when the new CEO opens the third-quarter call by saying he exceeded expectations, the bar is worth checking. It was low. But it was, for the first time in a year, cleared.

“We exceeded our expectations for top line performance in the third quarter with sequential revenue growth of 6.3% and an improvement across the business.” — Everett Cunningham, President and CEO · 2026-11-09

Revenue of $35 million was up 6.3% from Q2, though still 13.1% below the $40.2 million of Q3 2025 — a gap that narrows to 8.6% once you strip out $2.4 million of last year's terminated development program and add back Akoya's pre-acquisition stub. The recovery was broad: consumable growth led, spatial consumables hit their second-highest level ever, and the Americas posted high-teens sequential growth. Even the long-troubled Accelerator Lab — now the single most prominent theme on the call — booked a second consecutive quarter of book-to-bill approaching 2x on roughly $2.9 million of revenue.

The guide says recovery; the math says runway

Full-year guidance was narrowed to $142–146 million, implying a Q4 midpoint near $40 million — a ~14% sequential step-up that management insists is built bottoms-up, rep by rep. The CFO flagged Accelerator conversion as the highlight, and instrument placements as the swing factor. But analysts noticed the midpoint moved down, not up, and the quarter's most revealing exchange was about cash:

Due to additional demands on our cash in the quarter from spending and timing of working capital movements, cash usage was $16.2 million in the quarter. We ended Q3 with a cash balance of approximately $80.7 million.

Jason Faessler, Chief Financial Officer · 2026-11-09

Year-end cash is guided to roughly $70 million, with no debt. At the current burn, that is about five quarters of oxygen against a cash-flow breakeven target that has already been pushed once — from 2026 to 2027 — and is now defended purely on volume.

“One of the biggest levers of achieving that next year will be revenue and I think that's it simply.” — Jason Faessler, Chief Financial Officer · 2026-11-09

Worth remembering that in August the CFO was already saying the company was “fully committed to cash break-even in 2027” — Jason Faessler, Chief Financial Officer · 2026-08-10 while declining to talk about 2027 revenue. The cash flow breakeven promise has not moved this quarter — but the number that has to be true for it to hold has never been disclosed.

Florida is the new keyword — and it isn't a product story

The genuinely new thing at Quanterix this quarter isn't scientific. It's地理 — geography. Florida and Medicaid jumped into the top of the company's keyword set for the first time, on the back of Florida House Bill 885: coverage of blood-based Alzheimer's biomarker testing effective November 1, retroactive to July 2026, at a finalized $484 per test, for a Medicaid population of over 4 million. It is a reimbursement event, not a revenue event — LucentAD Complete revenue was called "relatively immaterial" on the call and twice deferred by the CFO.

The scale lever, then, is commercial partnerships: two new clinical reference labs (Sherman Abrams across the NY/NJ tri-state, TruPath spanning 14 states), both not yet operational, with a diagnostics team of roughly 20 people under a new GM hired out of Quest. Tests more than doubled sequentially — off a base small enough that management won't publish it. That is the honest shape of the story: real directional progress, invisible in the P&L.

The prior calls confirm this is a multi-quarter build, not a new claim. In May the CFO said the company was “not counting on revenues from direct testing in 2026” — Vandana Sriram, Chief Financial Officer · 2026-05-06. That hasn't changed; what changed is that a payer finally printed a number.

What management stopped saying

Two silences matter more than anything said out loud.

First, the FDA. In March, the CEO laid out a clean timeline for the five-marker LucentAD Complete 510(k): filed in January, six to nine months, clearance “by Q4 of this year” — Everett Cunningham, President and CEO · 2026-03-03. In August, still "end of this year." On Monday, the language evaporated into “while we cannot predict FDA timing” — Everett Cunningham, President and CEO · 2026-11-09 — with the same breath noting that Roche and C2N have now been approved, which "legitimizes the market" but also means competitors cleared the bar first. The FDA clearance keyword has been decaying as a company theme for two quarters; the FDA approval talk is now framed as an industry event rather than Quanterix's own.

Second, and stranger: Simoa ONE is gone. It was the company's number-one keyword entering 2026, discussed on the first-quarter call as being in early access with customers steering the next-gen HD-X roadmap. It does not appear on the third-quarter call at all. For a company whose bull case rests on ultrasensitive protein detection, the quiet retirement of the next-generation platform from the narrative — with capital redirected to a 2027 spatial oncology and ADC panel roadmap — is a capital-allocation statement management hasn't made explicitly.

The tape is voting elsewhere

Here is the irony. Over the last 90 days, the market's life science tools basket has been an advancer — TMO, DHR, BIO, MRVI and peers up double digits — and point of care diagnostics names have rallied alongside. Quanterix, sitting squarely in both themes, fell 21%. The market is not disputing the sector; it is disputing the balance sheet. At 1.3x price-to-revenue, the equity is priced as an option on cash, not on assays.

The fundamentals bear that out. The filings show revenue that quadrupled on the Akoya deal, a gross margin that has stabilized near 38.5% GAAP (47.4% non-GAAP, up 150bp year-over-year on Akoya synergies), and free cash flow that has been negative for every year of the company's public life. Operating expenses of $35.4 million non-GAAP were down $2.8 million year-over-year — disciplined, but not enough to close a $12.2 million adjusted EBITDA hole in a quarter.

The bull case for Quanterix in November 2026 is narrow but real: one quarter of sequential growth, a repeatable Accelerator bookings pattern, a payer that finally set a price, and a $70 million ending cash balance that buys time. The bear case is that the two things that would change the story fastest — an FDA clearance and a next-generation platform — were both promised loudly in prior quarters and both went quiet in this one. The next Catalyst isn't a product launch. It's a Q4 that has to deliver roughly 14% sequential growth on a guide whose midpoint already came down.